Barclays PLC boosted its holdings in Celcuity Inc. (NASDAQ:CELC - Free Report) by 567.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 53,605 shares of the company's stock after buying an additional 45,576 shares during the quarter. Barclays PLC owned 0.14% of Celcuity worth $800,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. nVerses Capital LLC bought a new stake in shares of Celcuity in the third quarter worth approximately $33,000. Prospera Private Wealth LLC purchased a new stake in Celcuity in the third quarter worth approximately $35,000. Values First Advisors Inc. bought a new stake in Celcuity in the 3rd quarter worth approximately $86,000. Quest Partners LLC raised its stake in Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company's stock valued at $95,000 after buying an additional 1,379 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Celcuity during the 3rd quarter valued at $119,000. Institutional investors own 63.33% of the company's stock.
Analyst Ratings Changes
Several analysts recently commented on CELC shares. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price objective on shares of Celcuity in a report on Friday, November 15th. Stifel Nicolaus boosted their price target on Celcuity from $39.00 to $42.00 and gave the company a "buy" rating in a research note on Monday, October 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $23.00 price target on shares of Celcuity in a research report on Friday, November 15th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $29.17.
Read Our Latest Stock Analysis on Celcuity
Celcuity Stock Performance
NASDAQ:CELC traded down $0.04 during mid-day trading on Wednesday, hitting $13.09. 189,655 shares of the company traded hands, compared to its average volume of 280,366. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock's fifty day moving average price is $13.63 and its 200-day moving average price is $15.29. The firm has a market cap of $486.03 million, a price-to-earnings ratio of -5.02 and a beta of 0.74. Celcuity Inc. has a one year low of $11.51 and a one year high of $22.19.
About Celcuity
(
Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Featured Articles
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
